Skip to Navigation Skip to Search Skip to Content
Search All Centers

Emerging Treatment Approaches for BRCA-Positive Breast Cancer Patients

Published on December 5, 2016

What is the EMBRACA study? Why are clinical trials important? Patient Power host Moira Quinn interviews her physician, Dr. Kimberly Blackwell, who is Director of the Breast Cancer Research Program at Duke Cancer Institute. They discuss the EMBRACA study--a randomized study evaluating Talazoparib (BMN 673), a PARP inhibitor in advanced or metastatic breast cancer patients who have the BRCA mutation.

Featuring

You might also like